Company profile: Abivax
1.1 - Company Overview
Company description
- Provider of clinical-stage biotechnology therapies that mobilize the body's natural immune machinery to treat autoimmune diseases, viral infections, and cancer, including obefazimod for ulcerative colitis (Phase 3), planned Phase 2b for Crohn's disease, exploration as combination therapy for ulcerative colitis in preclinical studies, and nonclinical evaluation for additional chronic inflammatory indications.
Products and services
- Obefazimod for Ulcerative Colitis: A late-stage clinical candidate in Phase 3 demonstrating anti-inflammatory activity in moderately to severely active UC, mobilizing natural immune machinery to reduce inflammation
- Obefazimod for Crohn’s Disease: A Phase 2b-ready investigational therapy planned for Crohn’s, leveraging anti-inflammatory properties and prior UC Phase 2 success to address Crohn’s disease inflammation
- Obefazimod for Other Inflammatory Indications: A nonclinical-stage exploratory program assessing additional chronic inflammatory conditions, with a trial indication declaration planned in 2024 to expand anti-inflammatory applications
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Abivax
Fio
HQ: Canada
Website
- Description: Provider of a point-of-care medical device used to gather data through interactions with a healthcare system.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Fio company profile →
Mymetics
HQ: Switzerland
Website
- Description: Provider of virosome-based vaccine R&D and immunotherapies, focused on next-generation preventative vaccines for infectious diseases. Pipeline includes HIV-1/AIDS, intranasal influenza, malaria, herpes simplex virus and RSV, plus candidates for Covid-19 and COP allergy immunotherapy, and research collaborations in cancer immunotherapy. Swiss-based with a research lab in the Netherlands.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Mymetics company profile →
BioMed Diagnostics
HQ: United States
Website
- Description: Provider of highly selective pre-plated prepared media culture devices that combine inoculation, culture, transport, and result analysis to reduce lab labor and costs. Solutions span clinical, veterinary point-of-care, and industrial microbiology for environmental monitoring and compliance, including InPouch, InTray, and PCR-compatible Transit Tube.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioMed Diagnostics company profile →
Lodo Therapeutics
HQ: United States
Website
- Description: Provider of drug discovery and development focused on creating naturally derived novel therapeutics to impact global human health, working in partnership with global pharmaceutical companies and leading NGOs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lodo Therapeutics company profile →
Pherecydes Pharma
HQ: France
Website
- Description: Provider of innovative biotechnology focused on developing personalized phage therapy to treat bacterial infections. The company develops bacteriophages against infections and has launched a multicenter European phage therapy trial to evaluate treatment on infected burn wounds.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Pherecydes Pharma company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Abivax
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Abivax
2.2 - Growth funds investing in similar companies to Abivax
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Abivax
4.2 - Public trading comparable groups for Abivax
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →